Мифы о диетах. Наука о том, что мы едим

3. Жиры, итого

1. de Nijs, T., Crit Rev Clin Lab Sci (Nov 2013); 50 (6): 163–71. ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management.

2. Kaur, N., J Food Sci Technol (Oct 2014); 51 (10): 2289–303. Essential fatty acids as functional components of foods, a review.

3. Chowdhury, R., Ann Intern Med (18 Mar 2014); 160 (6): 398–406. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis.

4. Würtz, P., Circulation (8 Jan 2015). pii: 114.013116. Metabolite profiling and cardiovascular event risk: a prospective study of three population-based cohorts.

5. Albert, B.B., Sci Rep (21 Jan 2015); 5: 7928. doi: 10.1038/­srep07928. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA.

6. Ackman, R.G., J Am Oil Chem Soc (1989); 66: 1162–64. EPA and DHA contents of encapsulated fish oil products.

7. Opperman, M., Cardiovasc J Afr (2011); 22: 324–29. Analysis of omega-3 fatty acid content of South African fish oil supplements.

8. Micha, R., BMJ (2014); 348: g2272. Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys.

9. Campbell, T.C., Am J Cardiol (26 Nov 1998); 82 (10B): 18T–21T. Diet, lifestyle, and the etiology of coronary artery disease: the Cornell China study.

10. Campbell, T.C., The China Study (BenBella Books, 2006).

4. Жиры насыщенные

1. Law, M., BMJ (1999); 318: 1471–80. Why heart disease mortality is low in France: the time lag explanation.

2. Bertrand, X., J Appl Microbiol (Apr 2007); 102 (4): 1052–9. Effect of cheese consumption on emergence of antimicrobial resistance in the intestinal microflora induced by a short course of amoxicillin-clavulanic acid.

3.https://­www.youtube.com/­watch?v=134aMOQwyhY.

4. David, L.A., Nature (23 Jan 2014); 505 (7484): 559–63.

5. Teicholz, N., The Big Fat Surprise (Simon & Schuster, 2014)

6. Goldacre, B., BMJ (2014); 349 doi: http://­dx.doi.org/­10.1136/­bmj.g4745. Mass treatment with statins.

7. Harborne, Z., Open Heart (2015); 2: doi: 10.1136/­openhrt-2014-000196. Evidence from randomised controlled trials did not support the introduction of dietary fat guidelines in 1977 and 1983: a systematic review and meta-analysis.

8. Siri-Tarino, P.W., Am J Clin Nutr (2010); 91: 535–46. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease.

9. Hjerpsted, J., Am J Clin Nutr (2011); 94: 1479–84. Cheese intake in large amounts lowers LDL-cholesterol concentrations compared with butter intake of equal fat content.

10. Rice, B.H., Curr Nutr Rep (15 Mar 2014); 3: 130–38. Dairy and Cardiovascular Disease: A Review of Recent Observational Research.

11. Tachmazidou, I., Nature Commun (2013); 4: 2872. A rare functional cardioprotective APOC3 variant has risen in frequency in distinct population isolates.

12. Minger, D., Death by Food Pyramid (Primal Blueprint, 2013).

13. Chen, M., Am J Clin Nutr (Oct 2012); 96 (4): 735–47. Effects of dairy intake on body weight and fat: a meta-analysis of randomized controlled trials.

14. Martinez-Gonzalez, M., Nutr Metab Cardiovasc Dis (Nov 2014); 24 (11): 1189–96. Yogurt consumption, weight change and risk of overweight/obesity: the SUN cohort.

15. Jacques, P., Am J Clin Nutr (May 2014); 99 (5): 1229S–34S. Yogurt and weight management.

16. Kano, H., J Dairy Sci (2013); 96: 3525–34. Oral administration of Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 suppresses inflammation by decreasing interleukin-6 responses in a murine model of atopic dermatitis.

17. Daneman, N., Lancet (12 Oct 2013); 382 (9900): 1228–30. A probiotic trial: tipping the balance of evidence?

18. Guo, Z., Nutr Metab Cardiovasc Dis (2011); 21: 844–50. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials.

19. Jones, M.L., Br J Nutr (May 2012); 107 (10): 1505–13. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults.

20. Jones, M.L., Eur J Clin Nutr (2012); 66: 1234–41. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial.